Flagship pulls in its biggest VC round
Flagship Pioneering, the money and minds behind Moderna Therapeutics and more than 75 other life sciences businesses, has raised $824 million in venture capital to bankroll startups, the company’s largest single fundraising effort.
Not that Moderna fits that description anymore. The former unicorn’s IPO set a record late last year, when its valuation tipped the scales at roughly $7.5 billion as it sought to raise $500 million. But Moderna is the type of company that would have gotten money from the new “special opportunities” pool for startups, Noubar Afeyan, founder and chief executive of Flagship, told the Boston Globe’s Jonathan Saltzman.
Not that Moderna fits that description anymore. The former unicorn’s IPO set a record late last year, when its valuation tipped the scales at roughly $7.5 billion as it sought to raise $500 million. But Moderna is the type of company that would have gotten money from the new “special opportunities” pool for startups, Noubar Afeyan, founder and chief executive of Flagship, told the Boston Globe’s Jonathan Saltzman.
No hay comentarios:
Publicar un comentario